117 related articles for article (PubMed ID: 35922063)
1. CRISPR Activation Screening Identifies VGLL3-TEAD1-RUNX1/3 as a Transcriptional Complex for PD-L1 Expression.
Wijdeven RH; Cabukusta B; Behr FM; Qiu X; Amiri D; Borras DM; Arens R; Liang Y; Neefjes J
J Immunol; 2022 Sep; 209(5):907-915. PubMed ID: 35922063
[TBL] [Abstract][Full Text] [Related]
2. RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions.
Klubíčková N; Agaimy A; Hájková V; Ptáková N; Grossmann P; Šteiner P; Michal M; Michal M
Virchows Arch; 2022 Oct; 481(4):613-620. PubMed ID: 35776191
[TBL] [Abstract][Full Text] [Related]
3. VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle.
Figeac N; Mohamed AD; Sun C; Schönfelder M; Matallanas D; Garcia-Munoz A; Missiaglia E; Collie-Duguid E; De Mello V; Pobbati AV; Pruller J; Jaka O; Harridge SDR; Hong W; Shipley J; Vargesson N; Zammit PS; Wackerhage H
J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31138678
[TBL] [Abstract][Full Text] [Related]
4. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
Xu Y; Chen C; Guo Y; Hu S; Sun Z
Front Immunol; 2022; 13():848327. PubMed ID: 35300341
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract][Full Text] [Related]
7. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y
Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671
[TBL] [Abstract][Full Text] [Related]
8. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
9. A novel model of controlling PD-L1 expression in ALK
Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
[TBL] [Abstract][Full Text] [Related]
10. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
12. IFN-γ-induced PD-L1 expression on human melanocytes is impaired in vitiligo.
Willemsen M; Krebbers G; Tjin EPM; Willemsen KJ; Louis A; Konijn VAL; Narayan VS; Post NF; Bakker WJ; Melief CJM; Bekkenk MW; Luiten RM
Exp Dermatol; 2022 Apr; 31(4):556-566. PubMed ID: 34758170
[TBL] [Abstract][Full Text] [Related]
13. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
14. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
15. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
16. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-1
Singh A; Mohan A; Dey AB; Mitra DK
Clin Exp Immunol; 2017 Feb; 187(2):269-283. PubMed ID: 27665733
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens.
Papalexi E; Mimitou EP; Butler AW; Foster S; Bracken B; Mauck WM; Wessels HH; Hao Y; Yeung BZ; Smibert P; Satija R
Nat Genet; 2021 Mar; 53(3):322-331. PubMed ID: 33649593
[TBL] [Abstract][Full Text] [Related]
19. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
